Why People Respond So Differently to Cannabinoids: Pharmacogenomics and Individual Variation

Two people take the same cannabinoid preparation at the same dose for the same number of weeks. One notices a meaningful shift in how they feel — sleep is more settled, the edge of chronic stress is less sharp, recovery is somewhat better. The other notices nothing at all. Both are reporting accurately. Both experiences are consistent with what the research predicts about cannabinoid pharmacology. Individual variation in cannabinoid response is not a placebo question, not a product quality question, and not evidence that one person is more susceptible to suggestion than the other. It is a documented pharmacological reality with identifiable biological sources.

FAAH Genetics — The Most Studied Source of Variation

FAAH — fatty acid amide hydrolase — is the primary enzyme responsible for degrading anandamide, the body's own cannabinoid. The faster FAAH breaks down anandamide, the lower the resting anandamide tone. The slower FAAH operates, the higher the anandamide available at any given moment. CBD's primary mechanism — one of its most replicated findings — is inhibition of FAAH, which allows anandamide to persist longer rather than being immediately degraded. The magnitude of CBD's effect on anandamide availability therefore depends substantially on how active a given person's FAAH enzyme is to begin with.

FAAH activity is substantially heritable. A common single nucleotide polymorphism in the FAAH gene — the C385A variant — produces a less stable enzyme that degrades more rapidly, effectively reducing FAAH activity. Individuals who carry the A allele of this variant have lower baseline FAAH activity, higher resting anandamide tone, and — based on published research — different baseline anxiety profiles, different stress reactivity, and measurably different responses to cannabinoid preparations that work through the FAAH pathway. A 2009 study by Hariri and colleagues found that carriers of the FAAH C385A variant showed reduced amygdala reactivity to threatening stimuli, consistent with higher resting anandamide tone providing a natural anxiolytic buffer. Separate work by Sipe and colleagues found FAAH C385A associated with reduced anxiety and pain sensitivity in human populations.

The practical implication for cannabinoid response: an individual with already-low FAAH activity and high resting anandamide tone may experience less noticeable benefit from a FAAH-inhibiting preparation like CBD, because the system it is working on is already operating near its ceiling. An individual with high FAAH activity and low resting anandamide tone may experience more noticeable benefit from the same preparation for the same reason. Neither response is wrong. Both are predictable from the genetics and the mechanism.

CB1 Receptor Density and Endocannabinoid Tone

CB1 receptor density — how many CB1 receptors are expressed in key brain regions — varies between individuals, is influenced by genetics, and changes in response to chronic stress and cannabinoid exposure. Higher CB1 density in stress-regulatory regions like the prefrontal cortex, hippocampus, and amygdala is associated with more robust endocannabinoid signalling in those circuits. Lower density means the same endocannabinoid signal produces a smaller response at the receptor level.

The CNR1 gene — which encodes the CB1 receptor — has multiple documented polymorphisms that affect receptor expression, binding affinity, and downstream signalling. Several of these variants have been associated with differences in anxiety, stress reactivity, depression risk, and response to cannabis-related compounds in published genetic association studies. The specific clinical implications of CNR1 variants for non-intoxicating cannabinoid response in humans remain an active research area, but the basic principle is established: receptor-level genetics create a second layer of individual variation independent of enzyme genetics.

Baseline endocannabinoid tone — the resting level of endocannabinoid system activity — varies between individuals for reasons that are only partially explained by genetics. Chronic stress reduces ECS tone. Physical activity increases it. Sleep quality affects it. Diet affects it. A person whose ECS has been chronically suppressed by sustained stress load has a different starting point than a person whose ECS is well-maintained — and both will respond differently to exogenous cannabinoid input at the same dose.

Metabolism — The CYP450 Layer

Cannabinoids are metabolised primarily by CYP3A4 and CYP2C9 — liver enzymes that also process a significant proportion of pharmaceutical drugs. CYP enzyme activity varies substantially between individuals based on genetic polymorphisms, and is classified into four phenotypes: poor metabolisers, intermediate metabolisers, normal metabolisers, and ultra-rapid metabolisers. A poor metaboliser of CYP3A4 will have higher plasma concentrations of cannabinoids from the same oral dose than a rapid metaboliser, producing more pronounced effects at the same dose. An ultra-rapid metaboliser may clear cannabinoids so quickly that an otherwise effective dose is pharmacologically insufficient by the time it reaches relevant concentrations.

This metabolic variation also underlies the drug interaction concerns associated with CBD specifically — CBD inhibits CYP3A4 and CYP2C9, which can raise plasma levels of medications processed by those enzymes. The magnitude of that interaction depends on the individual's baseline CYP activity, which is not uniform. CYP pharmacogenomics is the most clinically mature area of cannabinoid individual variation research, largely because CYP variation has been extensively studied in pharmaceutical contexts for decades before cannabinoid research began to draw on it.

What This Means for Evaluating Your Own Response

The practical implications of individual variation are specific and worth naming clearly.

A response that is absent or minimal at one dose may become present at a higher dose — because the pharmacologically relevant concentration threshold varies by individual based on receptor density, enzyme activity, and metabolic rate. Dose titration — starting lower and adjusting upward over weeks — is not a commercial suggestion to use more product. It is a pharmacological necessity given individual variation in what constitutes an effective concentration.

A response that is present but subtle may reflect a well-functioning ECS that does not have a pronounced deficit to correct — rather than a preparation that is not working. The ECS is a homeostatic system. Preparations that support it may produce more noticeable effects in individuals whose ECS is significantly dysregulated, and subtler effects in individuals whose ECS is closer to optimal function. Neither response means the preparation is or is not working in a pharmacological sense.

A response that begins after several weeks rather than immediately is consistent with what is understood about ECS adaptation and FAAH modulation timelines. Endocannabinoid system changes operate on timescales of days to weeks, not hours. Evaluating cannabinoid response at two days is not pharmacologically meaningful. Evaluating at four to six weeks provides a more accurate picture.

None of this removes the role of placebo and expectation effects, which are real, well-documented, and not dismissible. What it does establish is that when genuine pharmacological effects are present, their magnitude and character will vary between individuals for documented biological reasons — and that the absence of a noticeable response is not simply a product or placebo question. It may be a FAAH genetics question, a receptor density question, a metabolic rate question, or an ECS tone question. The answer to each of those is individual and, with current technology, largely inaccessible without genetic testing that is not routinely available.

Drug Interactions as a Source of Variable Response

A pattern worth naming specifically: people taking common medications — particularly antihistamines and antidepressants — frequently report either absent response or unexpected side effects when using cannabinoid preparations. Both experiences have documented pharmacological explanations that are distinct from the genetic sources of variation described above.

First-generation antihistamines — diphenhydramine (Benadryl), hydroxyzine — produce sedation and blunt interoceptive awareness through anticholinergic and CNS-depressant mechanisms. Interoception — the perception of internal physiological states — is the primary channel through which subtle cannabinoid effects are noticed. A medication that reduces interoceptive sensitivity can effectively mask cannabinoid effects that are pharmacologically present but imperceptible. Second-generation antihistamines — cetirizine (Zyrtec), loratadine (Claritin) — are less sedating but some interact with CYP3A4, the primary enzyme that metabolises cannabinoids, altering how quickly cannabinoids are cleared from circulation.

Antidepressants — particularly SSRIs and SNRIs — represent a different interaction pattern. CBD inhibits CYP2D6, the enzyme that metabolises many SSRIs including fluoxetine (Prozac), paroxetine (Paxil), and duloxetine (Cymbalta). When CBD slows CYP2D6 activity, SSRI plasma levels can rise above their usual range — producing dose-related side effects including nausea, headache, and agitation that are correctly attributed to the SSRI rather than to the cannabinoid. A person who experiences nausea after starting a CBD preparation while on an SSRI may be experiencing mild SSRI elevation, not a direct response to CBD.

These interaction patterns are not rare edge cases. They affect a substantial proportion of the adult population on polypharmacy regimens. Anyone using cannabinoid preparations alongside prescription medications — particularly antihistamines, antidepressants, or any medication with a narrow therapeutic window — should discuss this with their prescribing physician. A dedicated article on cannabinoid drug interactions covers the full interaction landscape in more detail.